Based on immunophenotyping tumours, we speculate that this differential effect may, in part, be attributed to the capacity of anti-CTLA-4 blocking the CTLA-4 immunosuppressive properties such as attenuation of CD28 signalling through binding of CD80/8635,52,53. This evidence concerns the gene CTLA4 and neoplasm.